Martin H Ruwald1, Xiaorong Xu Parks2, Arthur J Moss3, Wojciech Zareba3, Jayson Baman3, Scott McNitt3, Jorgen K Kanters4, Wataru Shimizu5, Arthur A Wilde6, Christian Jons7, Coeli M Lopes8. 1. Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York; Department of Cardiology, Gentofte Hospital, Hellerup, Denmark. 2. Cardiovascular Research Institute, Department of Medicine, University of Rochester, Rochester, New York. 3. Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York. 4. Department of Cardiology, Gentofte Hospital, Hellerup, Denmark; Laboratory of Experimental Cardiology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. 5. Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan. 6. AMC Heart Centre, Department of Clinical and Experimental Cardiology, Academic Medical Centre, Amsterdam, The Netherlands. 7. Department of Cardiology, Gentofte Hospital, Hellerup, Denmark. 8. Cardiovascular Research Institute, Department of Medicine, University of Rochester, Rochester, New York. Electronic address: coeli_lopes@urmc.rochester.edu.
Abstract
BACKGROUND: In long QT syndrome type 1 (LQT1), the location and type of mutations have been shown to affect the clinical outcome. Although haploinsufficiency, including stop-codon and frameshift mutations, has been associated with a lower risk of cardiac events in patients with LQT1, nonsense mutations have been presumed functionally equivalent. OBJECTIVE: The purpose of this study was to evaluate clinical differences between patients with nonsense mutations. METHODS: The study sample comprised 1090 patients with genetically confirmed mutations. Patients were categorized into 5 groups, depending on mutation type and location: missense not located in the high-risk cytoplasmic loop (c-loop) (n = 698), which is used as reference; missense c-loop (n = 192); stop-codon (n = 67); frameshift (n = 39); and others (n = 94). The primary outcome was a composite end point of syncope, aborted cardiac arrest, and long QT syndrome-related death (cardiac events). Outcomes were evaluated using the multivariate Cox proportional hazards regression analysis. Standard patch clamp techniques were used. RESULTS: Compared to patients with missense non-c-loop mutations, the risk of cardiac events was reduced significantly in patients with stop-codon mutations (hazard ratio [HR] 0.57; 95% confidence interval [CI] 0.34-0.96; P = .035), but not in patients with frameshift mutations (HR 1.01; 95% CI 0.58-1.77; P = .97). Our data suggest that currents of the most common stop-codon mutant channel (Q530X) were larger than those of haploinsufficient channels (wild type: 42 ± 6 pA/pF, n = 20; Q530X+wild type: 79 ± 14 pA/pF, n = 20; P < .05) and voltage dependence of activation was altered. CONCLUSION: Stop-codon mutations are associated with a lower risk of cardiac events in patients with LQT1, while frameshift mutations are associated with the same risk as the majority of the missense mutations. Our data indicate functional differences between these previously considered equivalent mutation subtypes.
BACKGROUND: In long QT syndrome type 1 (LQT1), the location and type of mutations have been shown to affect the clinical outcome. Although haploinsufficiency, including stop-codon and frameshift mutations, has been associated with a lower risk of cardiac events in patients with LQT1, nonsense mutations have been presumed functionally equivalent. OBJECTIVE: The purpose of this study was to evaluate clinical differences between patients with nonsense mutations. METHODS: The study sample comprised 1090 patients with genetically confirmed mutations. Patients were categorized into 5 groups, depending on mutation type and location: missense not located in the high-risk cytoplasmic loop (c-loop) (n = 698), which is used as reference; missense c-loop (n = 192); stop-codon (n = 67); frameshift (n = 39); and others (n = 94). The primary outcome was a composite end point of syncope, aborted cardiac arrest, and long QT syndrome-related death (cardiac events). Outcomes were evaluated using the multivariate Cox proportional hazards regression analysis. Standard patch clamp techniques were used. RESULTS: Compared to patients with missense non-c-loop mutations, the risk of cardiac events was reduced significantly in patients with stop-codon mutations (hazard ratio [HR] 0.57; 95% confidence interval [CI] 0.34-0.96; P = .035), but not in patients with frameshift mutations (HR 1.01; 95% CI 0.58-1.77; P = .97). Our data suggest that currents of the most common stop-codon mutant channel (Q530X) were larger than those of haploinsufficient channels (wild type: 42 ± 6 pA/pF, n = 20; Q530X+wild type: 79 ± 14 pA/pF, n = 20; P < .05) and voltage dependence of activation was altered. CONCLUSION: Stop-codon mutations are associated with a lower risk of cardiac events in patients with LQT1, while frameshift mutations are associated with the same risk as the majority of the missense mutations. Our data indicate functional differences between these previously considered equivalent mutation subtypes.
Authors: I Splawski; J Shen; K W Timothy; M H Lehmann; S Priori; J L Robinson; A J Moss; P J Schwartz; J A Towbin; G M Vincent; M T Keating Journal: Circulation Date: 2000-09-05 Impact factor: 29.690
Authors: L A Larsen; I Fosdal; P S Andersen; J K Kanters; J Vuust; G Wettrell; M Christiansen Journal: Eur J Hum Genet Date: 1999-09 Impact factor: 4.246
Authors: Jayson R Baman; James L Cox; Patrick M McCarthy; Daniel Kim; Ravi B Patel; Rod S Passman; Jane E Wilcox Journal: J Cardiovasc Electrophysiol Date: 2021-07-16 Impact factor: 2.942
Authors: Mario Torrado; Germán Fernández; Christian A Ganoza; Emilia Maneiro; Diego García; Natalia Sonicheva-Paterson; Isaac Rosa; Juan Pablo Ochoa; Luis Santomé; Elena Vasichkina; Lorenzo Monserrat Journal: NPJ Genom Med Date: 2021-03-04 Impact factor: 8.617
Authors: Charlotte Gibbs; Jacob Thalamus; Kristian Tveten; Øyvind L Busk; Jan Hysing; Kristina H Haugaa; Øystein L Holla Journal: J Am Heart Assoc Date: 2018-08-21 Impact factor: 5.501